Euro Manganese boosts Chvaletice after-tax NPV by US$25 million

|

Published 01-JUN-2021 11:10 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Euro Manganese Inc. (TSX-V/ASX:EMN) has entered into royalty termination agreements (Royalty Termination Agreements) to purchase and extinguish an aggregate 1.2% net smelter royalty (NSR) interest in the Chvaletice Manganese Project for an aggregate consideration of US$4.5 million (approximately CAD$5.45 million).

The 1.2% NSR was granted in connection with the company’s acquisition of its 100% interest in Mangan Chvaletice s.r.o. in May 2016 from three arm’s-length parties.

The Chvaletice Manganese Project entails reprocessing a significant manganese deposit hosted in mine tailings from a decommissioned mine strategically located in the Czech Republic in reasonably close proximity to industrial hubs where there is expected to be substantial demand for battery materials.

Based on a preliminary economic assessment (PEA) completed in early 2019, extinguishing the NSR interests would eliminate US$91.1 million in expenditures over the project’s 25-year life, reduce operating costs by US$3.40 per tonne of plant feed (or 2.5% of total cost per tonne of plant feed), while increasing the after-tax NPV of the project by US$25.3 million (approximately 4%) using the PEA’s 10% discount rate.

All economic assumptions and results will be updated as part of the project’s feasibility study targeted for completion in the first quarter of 2022.

Part of the consideration for the royalty purchase (US$900,000) was paid on May 21, 2021, while the remainder will be paid on or before 31 January 2022 in the form of all-cash or a combination of cash and up to 50% in shares.

Highlighting the financial impact of royalty termination, chief executive Marco Romero said, “Based on the 2019 PEA results and assumptions, this royalty buy-out enhances the project’s economics, and the payment terms allow the company substantial financial flexibility.

“We continue to evaluate other potential value-enhancing opportunities for the project.’’



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X